The Vaccine That Got Killed by Fear Is Back From the Dead
The last Lyme disease vaccine was killed by lawsuits, not science. Now Pfizer and Valneva's new candidate just hit a major regulatory milestone in Europe, and this time the stakes (and the tick populations) are much bigger.
In 1998, the world got its first Lyme disease vaccine. By 2002, it was gone. Not because it didn't work. Not because it was dangerous. It vanished because people were afraid of it.
Now, nearly a quarter century later, a new Lyme vaccine just cleared a major hurdle in Europe. And this time, the science is stronger, the need is bigger, and the stakes are enormous.
A Ghost Story With a Sequel
Let's rewind. LYMErix, made by SmithKline Beecham (later GlaxoSmithKline), was the only Lyme disease vaccine ever approved in the United States. It worked. Clinical trials proved it. The FDA signed off on it.
Then the lawsuits started.
People who got the shot claimed it caused arthritis. The media ran with the story. Class-action lawsuits piled up. Sales cratered. And in early 2002, GSK pulled it from the market.
The twist? Subsequent safety reviews never found evidence that the vaccine actually caused arthritis or any of the other claimed injuries. The data didn't support a causal link. LYMErix was essentially killed by fear, not by science. It became one of the most cautionary tales in vaccine history: a product that worked, withdrawn because public perception turned toxic.
For the next two decades, nobody touched Lyme vaccines with a ten-foot pole. The market sat empty while the disease kept spreading.
Meanwhile, the Ticks Kept Marching
Lyme disease didn't take a break just because the vaccine did. In fact, it got dramatically worse.
In the U.S., Lyme disease is the most common tick-borne illness, with an estimated 476,000 cases diagnosed and treated each year. That's not a typo. Nearly half a million Americans, annually.
Europe's numbers are staggering too. Surveillance data shows roughly 132,000 reported cases per year across the continent, with the highest rates in countries like Estonia, Finland, and Slovenia. Some local hotspots see more than 100 cases per 100,000 people annually.
And it's getting worse, not better. About 70% of European countries with recent surveillance data reported an average incidence increase of 36% in recent years. Infected ticks are spreading northward into Scandinavia. Climate change, shifting land use patterns, and changing human behavior are all pushing the boundaries of where ticks thrive.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
An estimated 223 million Europeans now live in high-incidence areas. That's roughly a quarter of the continent's population sharing their backyards with disease-carrying ticks, and there's been no vaccine available for any of them. Until, potentially, now.
Enter Pfizer and Valneva (With a Very Long Runway)
The partnership between Pfizer and the French biotech Valneva dates back to 2020, when the two companies struck a deal to co-develop VLA15, a Lyme disease vaccine candidate that targets six strains of the bacteria's outer surface protein (OspA). Think of OspA as the lock on the outside of the Lyme bacteria; the vaccine teaches your immune system to recognize that lock before the bacteria ever gets inside.
The deal's financial architecture tells you how seriously Pfizer took this. The original agreement included $130 million upfront to Valneva, with up to $308 million in total cash payments. In 2022, Pfizer doubled down, investing €90.5 million (about $95 million) for an 8.1% equity stake in Valneva. The revised deal adjusted cost-sharing (Valneva now covers 40% of remaining development costs) and set Pfizer's royalty rate at 14% to 22% of net sales.
Translation: Pfizer was betting big, and putting real money on the table to prove it.
The Trial That Almost Tripped Over Its Own Shoelaces
The companies ran a massive Phase 3 study called VALOR to test VLA15 in people aged five and older. The results told two slightly different stories, depending on which statistical lens you used.
The headline number: 73.2% efficacy at preventing Lyme disease, measured starting 28 days after the fourth dose. That sounds great, and clinically, it is. But the trial technically missed its primary statistical threshold. The reason? Fewer Lyme cases occurred during the study than expected, which made the confidence interval (the statistical range of certainty) wider than planned. The lower bound of the 95% confidence interval landed at 15.8%, just below the required 20% cutoff.
If that sounds confusing, here's the analogy: imagine you're testing whether a new batting coach actually improves a team's hitting. The players are hitting better, clearly, but because there were fewer games than expected in the season, you can't prove the improvement isn't partly due to luck. The improvement looks real, but the sample size makes you less certain.
A second prespecified analysis helped rescue the story. Measured from one day after the fourth dose, efficacy was 74.8%, and this time the lower bound of the confidence interval cleared the 20% bar at 21.7%. Importantly, the vaccine was well tolerated, with no safety concerns identified.
So the trial was a messy win. Not a clean knockout, but enough to keep the program alive and moving toward regulators.
What Just Happened in Europe
On August 14, 2026, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Pfizer and Valneva's Lyme vaccine.
Let's be precise about what "validated" means, because it sounds more dramatic than it is. EMA validation is not approval. It's the agency confirming that the application package is complete enough to begin a formal scientific review. Think of it like a university confirming they received your application and it has all the required documents. You haven't been accepted yet, but you're officially in the review pile.
That said, this is genuinely significant. It means the EMA believes the data package (including those VALOR results and all the safety data) is substantive enough to warrant a full assessment. For a Lyme disease vaccine, that's a milestone that hasn't been reached in decades.
Analyst firm Stifel described the announcement as a "major de-risking event" for Valneva. Investors agreed: Valneva's stock jumped roughly 13% to 15% on the news.
The Road Ahead Is Long, But the GPS Is Working
If EMA's review follows typical timelines, an opinion on whether to authorize the vaccine could come around Q3 2027, according to analyst estimates. That means a European launch, if approved, likely wouldn't generate meaningful revenue until 2027 or 2028.
On the U.S. side, the picture is murkier. As of March 2026, Pfizer said it was "planning submissions to regulatory authorities," but there's no public confirmation that a formal application (called a BLA, or Biologics License Application) has been filed with the FDA yet. The original 2022 guidance pointed to a possible 2025 BLA filing, so the timeline has clearly shifted.
For Valneva specifically, the commercial upside is structured through the Pfizer partnership. If the vaccine gets approved and commercialized, Valneva stands to collect $143 million in commercialization milestones plus those 14% to 22% royalties. Not bad for a company that found a partner willing to handle the heavy lifting of late-stage development and global launch.
Why This Time Might Be Different
The ghost of LYMErix looms over everything. Any Lyme vaccine will face public skepticism, and the companies know it. But three things have changed since 2002.
First, the disease is dramatically worse. When LYMErix was on the market, Lyme disease was seen as a regional nuisance. Now it's a continental-scale public health problem affecting hundreds of millions of people in at-risk areas. The unmet need is impossible to ignore.
Second, the science is cleaner. VLA15 targets six OspA variants (LYMErix only targeted one), and the VALOR trial enrolled thousands of participants across multiple countries. The safety profile looks solid.
Third, the conversation about vaccines has evolved. The COVID-19 pandemic showed the world what vaccines can do at scale. It also showed that anti-vaccine sentiment hasn't gone away, of course, but the infrastructure for communicating vaccine safety has improved.
None of this guarantees success. The trial's statistical wobble gives critics something to point at. The regulatory review could raise questions. And the commercial launch (in Europe and eventually the U.S.) will require navigating the same public perception challenges that killed LYMErix.
But for the first time in over 20 years, a Lyme disease vaccine is in active regulatory review. Hundreds of millions of people in tick-endemic regions are waiting. The ticks, unfortunately, are not.
The Bottom Line
Pfizer and Valneva's Lyme disease vaccine just got its application validated by the EMA, making it the first Lyme vaccine candidate to reach this stage in decades. The Phase 3 data showed roughly 74% efficacy with a clean safety profile, though the statistics were messier than anyone wanted. If the review goes well, Europe could have a Lyme vaccine by late 2027, with U.S. filing still pending.
After 24 years of nothing, the ticks finally have competition.
Deals & M&A5 min read
PTC Just Bought a Gene Therapy Out of Bankruptcy. It Might Be Brilliant.
PTC Therapeutics just scooped up a near-approval Fabry disease gene therapy from Sangamo's bankruptcy auction for $211 million. It's either the deal of the year or a cautionary tale waiting to happen.
